-
Microneedle Patch Delivery of Risedronate Sodium for Osteopo
2026-04-30
This study presents a dissolving microneedle transdermal patch incorporating Risedronate Sodium and Ursolic acid nanotransfersomes to enhance osteoporosis therapy. The optimized patch demonstrated high entrapment efficiency, sustained drug release, and significant ex vivo skin permeation, addressing key limitations of oral bisphosphonate delivery.
-
Optimizing Cancer Assays with Dovitinib (TKI-258, CHIR-258)
2026-04-30
This article provides scenario-driven guidance for using Dovitinib (TKI-258, CHIR-258) (SKU A2168) to address persistent challenges in cell viability, proliferation, and cytotoxicity assays. Through real laboratory scenarios, we demonstrate how this multitargeted RTK inhibitor enhances reproducibility and data integrity, supporting advanced oncology workflows. Researchers will find actionable protocols and evidence-based insights for SKU A2168.
-
Imipramine in Cancer and Neuroscience: Applied Protocols & T
2026-04-29
Imipramine, a classic tricyclic antidepressant, is now powering advanced research in glioma autophagy, HL-60 apoptosis, and neuroprotection. This article delivers stepwise workflows, actionable troubleshooting, and strategic insight for leveraging Imipramine’s antitumor and immunomodulatory properties in translational bench studies.
-
SB 202190: Selective p38 MAP Kinase Inhibitor in Cancer & In
2026-04-29
SB 202190 (FHPI) is a potent, selective p38 MAP kinase inhibitor used in inflammation and cancer therapeutics research. It inhibits p38α/β with nanomolar potency and is validated in assembloid and apoptosis assay models.
-
Ibrexafungerp Activity Against Fluconazole-Resistant C. auri
2026-04-28
This study demonstrates that ibrexafungerp (MK 3118), a novel oral triterpenoid antifungal, exhibits consistent in vitro potency and in vivo efficacy against fluconazole-resistant Candida auris. These findings highlight ibrexafungerp’s potential as an alternative therapeutic agent for multidrug-resistant Candida infections, particularly where existing options are limited.
-
SR-202 PPARγ Antagonist: Redefining Precision in Insulin Res
2026-04-28
Explore how SR-202, a selective PPARγ antagonist, advances insulin resistance research with unparalleled specificity. This article delivers a novel, assay-focused perspective on SR-202's application in metabolic and inflammation studies.
-
Reliable In Vitro Transcription with HyperScribe SP6 High Yi
2026-04-27
This article addresses common laboratory transcription challenges and demonstrates how the HyperScribe™ SP6 High Yield RNA Synthesis Kit (SKU K1415) ensures reproducibility, flexibility, and data-backed performance for applications in capped RNA synthesis, RNAi, and RNA vaccine research. Practical scenarios illustrate how this SP6 RNA polymerase kit streamlines workflows for biomedical researchers, supported by quantitative and literature-based evidence.
-
Berberine Suppresses NLRP3 Inflammasome via SIRT6-AMPK in AF
2026-04-27
This study demonstrates that berberine inhibits NLRP3 inflammasome activation by upregulating the SIRT6-AMPK pathway, thereby reducing angiotensin II-induced atrial fibrosis and susceptibility to atrial fibrillation (AF). The findings clarify the mechanistic link between metabolic signaling and inflammatory pathways in the pathogenesis of AF, suggesting new translational research directions.
-
SAR131675 and VEGFR-3 Inhibition: Unraveling Lymphatic Signa
2026-04-26
Explore the advanced biology of SAR131675, a potent VEGFR-3 inhibitor, and its unique role in modulating lymphatic endothelial signaling within tumor microenvironments. Gain new insights beyond fibrosis and standard angiogenesis studies for innovative research applications.
-
XPO1 Inhibition Potentiates Platinum Chemotherapy in GCB-DLB
2026-04-25
This article reviews a 2026 study demonstrating that inhibiting XPO1 with selinexor enhances the cytotoxic effects of platinum-based chemotherapy in germinal-center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) cell lines. The findings suggest a promising strategy for overcoming drug resistance in relapsed or refractory DLBCL, supporting further clinical evaluation of XPO1 inhibitor-platinum combinations.
-
O-GlcNAcylation Links Wnt Signaling to Bone Formation via Gl
2026-04-24
The reference study uncovers how Wnt3a signaling stimulates bone formation by enhancing O-GlcNAcylation, which in turn rewires aerobic glycolysis in osteoblasts. This mechanism provides a molecular link between Wnt pathway activation and metabolic shifts critical for osteogenesis, with implications for therapeutic strategies in osteoporosis.
-
D2HG Biosensors Reveal Metabolic Shifts in cGAMP-Activated M
2026-04-24
Wang et al. (2025) have engineered D2HG biosensors (DHsers) by elucidating the structural mechanism of DhdR, enabling dynamic and sensitive detection of D-2-hydroxyglutarate in living cells. This work uncovers how STING pathway activation via cGAMP elevates D2HG in macrophages, offering new tools for probing metabolic-immune interactions.
-
Fangchinoline Reverses Lysosomal Disruption to Block H1N1 En
2026-04-23
Cheng et al. identify fangchinoline as a TFEB-driven modulator that restores lysosomal biogenesis, impeding H1N1 influenza virus infection. Their findings highlight the strategic value of targeting host lysosomal pathways to counteract viral immune evasion and advance antiviral therapeutics.
-
Genistein: Cytoskeleton, Tyrosine Kinase, and Translational
2026-04-23
This article explores the mechanistic and translational landscape of Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one) as a selective protein tyrosine kinase inhibitor, with a focus on its intersection with cytoskeleton-dependent autophagy and cancer chemoprevention. Drawing on recent mechanotransduction research, we provide strategic guidance for experimental design, protocol optimization, and clinical translation, while highlighting APExBIO’s Genistein as a best-in-class research tool.
-
Spiroplasma eriocheiris Entry Mechanisms in Drosophila S2 Ce
2026-04-22
This study elucidates the cellular entry mechanisms of Spiroplasma eriocheiris into Drosophila Schneider 2 (S2) cells, demonstrating reliance on clathrin-mediated endocytosis and macropinocytosis, but not cholesterol-dependent pathways. These findings clarify the pathogen’s infection route in invertebrate models and refine the experimental basis for host-pathogen interaction studies.